Skip to main content

1 Result(s)

within Xavier Nicolas Remove this filter Medicine & Public Health Remove this filter Internal Medicine Remove this filter

and

  1. Article

    Open Access

    Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II

    Alirocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly lowers low-density lipoprotein cholesterol levels.

    Xavier Nicolas, Nassim Djebli, Clémence Rauch, Aurélie Brunet… in Clinical Pharmacokinetics (2019)

    Download PDF (1725 KB) View Article